Trial Profile
A Randomised, cross-over study to compare the safety, tolerability and pharmacokinetics of inhaled PA101 (Patara Pharma) to currently used formulations (Nalcrom® oral solution, and IntalTM nebulizer solution) in healthy volunteers, indolent systemic mastocytosis (ISM) and allergic asthma patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Sodium cromoglicate (Primary) ; Sodium cromoglicate
- Indications Allergic asthma; Systemic mastocytosis
- Focus Adverse reactions; Pharmacokinetics
- 12 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society